Product Profiles: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation

NEW YORK, Jan. 16, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0760642/Product-Profiles-Targeted-Cancer-Therapies----Trend-towards-personalized-medicine-will-lead-to-market-fragmentation.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Introduction

The targeted therapies class boasts several of the top-selling anticancer brands, and has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade, several blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.

Features and benefits

* Includes targeted cancer therapy drug profiles and development overviews detailing the companies involved and the clinical data that led to approvals* Includes SWOT analysis of each brand in the targeted cancer therapies class* Overview of each brand's positioning in its marketed indications relative to its competitors and in terms of its ability to meet unmet needs* Analysis of the clinical and commercial attractiveness of the targeted cancer therapies

Highlights

As a growing number of companies strive to develop targeted cancer therapies, competition will inevitably become more intense as more agents in this class reach the market. In addition, increasing pharmacoeconomic pressures will dampen sales growth of drugs in this market as they tend to command a high price.In recent years an improved understanding of the heterogeneity of cancer tumors and their molecular pathogenesis has led to the development of targeted therapies designed to treat niche subsets of patients with specific genetic mutations.The co-development of companion diagnostics that can identify the patients that will most benefit from cancer treatment will become increasingly important for developers seeking approval of targeted therapies and the treatment of cancer will become more personalized

Your key questions answered

* Access detailed information about the drugs that make up the most lucrative class in the oncology market* Understand the key factors that led to the success of some targeted cancer therapy brands and the issues which have hindered the uptake of others* Understand how the targeted cancer therapies market will change in the future as developers target niche indications

Strategic scoping and focusDatamonitor key findingsRelated reportsOVERVIEWCatalystSummaryPRODUCT OVERVIEWTargeted cancer therapy brandsMARKETED PRODUCT PROFILESAdcetris (brentuximab vedotin; Seattle Genetics/Takeda)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessAfinitor (everolimus; Novartis)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessArzerra (ofatumumab; Genmab/GlaxoSmithKline)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessAvastin (bevacizumab; Genentech/Roche/Chugai)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessCaprelsa (vandetanib; AstraZeneca)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessErbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessGleevec (imatinib; Novartis)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessHerceptin (trastuzumab; Roche/Chugai)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessIressa (gefitinib; AstraZeneca)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessIstodax (romidepsin; Celgene)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessNexavar (sorafenib; Bayer Schering/Onyx)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessRevlimid (lenalidomide; Celgene)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessRituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessSprycel (dasatinib; Bristol-Myers Squibb)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessSutent (sunitinib; Pfizer)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessTarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessTasigna (nilotinib; Novartis)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessThalomid (thalidomide; Celgene)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessTorisel (temsirolimus; Pfizer)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessTykerb (lapatinib; GlaxoSmithKline)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessVectibix (panitumumab; Amgen)Drug profileDevelopment overviewSWOT analysisProduct positioningClinical and commercial attractivenessVelcade (bortezomib; Takeda

More  

Check our  

CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED